WASHINGTON (Reuters) - The lung cancer pill Iressa has shown surprising results for patients with advanced disease where it has been at least as effective as a standard chemotherapy treatment, researchers reported on Thursday. Patients who got the once-a-day pill made by AstraZeneca lived as long as those given the chemotherapy treatment Sanofi-Aventis' Taxotere or docetaxel, the international team of researchers found. This is second-line treatment, traditionally offered after a course of combined chemotherapies that can last months and is still considered the best approach to lung cancer. "The study is the first time in lung cancer that an oral biological agent has been tested head-to-head against chemotherapy," Dr. Edward Kim of the University of Texas M.D. Anderson Cancer Center in Houston and colleagues wrote in the Lancet medical journal. Kim's team tested 1,466 patients in 24 countries who had completed a first course of standard chemotherapy. Half got Ires